NanOlogy, LLC

NanOlogy, LLC is a privately held, clinical-stage oncology company based in Fort Worth, Texas, in the United States. It is focused on a local precision approach to treating solid tumors: rather than relying solely on systemic chemotherapy, NanOlogy aims to deliver concentrated drug directly to the disease site while minimizing the systemic toxicity that often limits combination regimens. The company's work is built on the Purcision particle engineering technology platform, which was developed by CritiTech, Inc. of Lawrence, Kansas, and licensed to NanOlogy for oncology applications. The Purcision platform precipitates dissolved drug substances using sonication and compressed supercritical fluid carbon dioxide to form stable large surface area microparticles (LSAMs) of pure drug. These microparticles contain no excipients or coating agents. Their disproportionately large surface area relative to particle size allows them to be retained at the disease site, where they act as a depot that continuously releases drug at high local concentration. Systemic drug levels and associated toxicity remain negligible. Feasibility of the technology has been established across multiple drug classes, including taxanes, platins, TKIs, and PARPIs. NanOlogy's therapeutic platform is composed of patented LSAMs of pure drug designed for tumor-directed therapy via intratumoral, peritoneal, intravesicular, inhalation, and other routes of local administration. Its lead investigational drugs are LSAM-PTX (LSAM-paclitaxel) and LSAM-DTX (LSAM-docetaxel). LSAM-PTX is being studied for ovarian cancer (intraperitoneal), prostate cancer (intratumoral), pancreatic cancer (intratumoral), pancreatic mucinous cysts (intracystic), and lung cancer (intratumoral/nodal), as well as in a nebulized inhalation formulation for lung cancer. LSAM-DTX is being evaluated for bladder cancer (resection bed injection and intravesical instillations) and renal cancer (intratumoral). Additional programs include LSAM-cisplatin for pediatric brain tumors and SOR007, a topical submicron particle paclitaxel suspension in an anhydrous base, for cutaneous metastases and actinic keratosis. According to the company, two clinical-stage investigational drugs, LSAM-PTX and LSAM-DTX, have completed clinical trials in multiple solid tumors with excellent tolerability and promising signs of tumor response and immunomodulation. NanOlogy states that clinical results across multiple solid tumors support the therapeutic potential of its LSAM investigational drugs in combination with systemic standard-of-care therapies for both local and metastatic disease, based on sustained tumoricidal response, anti-tumor immunomodulation, and minimal systemic toxicity. The company positions itself within the growing field of interventional oncology, where advances in accessing and precisely targeting solid tumors are increasing clinical interest in local precision therapy. NanOlogy operates as a private company and does not disclose a stock ticker or public listing. Its headquarters are in Fort Worth, Texas. The company maintains a corporate website at nanology.us, where it publishes information about its pipeline, technology, and upcoming events. As a clinical-stage enterprise, its activities center on research, development, and clinical trials rather than marketed commercial products; its investigational drugs have not been presented as approved therapies in the supplied evidence.

NanOlogy, LLC is a clinical-stage oncology company headquartered in Fort Worth, Texas, United States. The company was established to advance a local precision approach to treating solid tumors, aiming to improve tumor response without adding toxicity. Its core technology, the Purcision particle engineering platform, was developed by CritiTech, Inc. of Lawrence, Kansas, and licensed to NanOlogy for oncology applications. Purcision uses sonication and compressed supercritical fluid carbon dioxide to precipitate dissolved drug substances into stable large surface area microparticles (LSAMs) of pure drug, containing no excipients or coating agents. These LSAMs have a disproportionately large surface area to particle size ratio, which enables retention at the disease site and continuous local therapeutic drug release over time, with gradual systemic elimination at subtoxic levels. The feasibility of the Purcision technology has been established in multiple drug classes, including taxanes, platins, TKIs, and PARPIs. NanOlogy's therapeutic platform is composed of patented LSAMs of pure drug designed for tumor-directed therapy via intratumoral, peritoneal, intravesicular, inhalation, and other routes of local administration. Two clinical-stage investigational drugs, LSAM-PTX (LSAM-paclitaxel) and LSAM-DTX (LSAM-docetaxel), have completed clinical trials in multiple solid tumors with excellent tolerability and promising signs of tumor response and immunomodulation, according to the company. Clinical trials are underway by NanOlogy in multiple therapeutic areas to evaluate local delivery of concentrated, sustained investigational drugs to increase solid tumor response, eliminate toxicities associated with systemic agents, and promote anti-tumor immunomodulation. The company's pipeline includes LSAM-PTX for ovarian cancer (intraperitoneal), prostate cancer (intratumoral), pancreatic cancer (intratumoral), pancreatic mucinous cysts (intracystic), and lung cancer (intratumoral/nodal); LSAM-DTX for bladder cancer (resection bed injection/intravesical instillations) and renal cancer (intratumoral); LSAM-cisplatin for pediatric brain tumors; LSAM-PTX for nebulized inhalation for lung cancer; and SOR007, a topical submicron particle paclitaxel suspended in an anhydrous base, for cutaneous metastases and actinic keratosis. NanOlogy states that clinical results across multiple solid tumors support the therapeutic potential of its LSAM investigational drugs in combination with systemic standard-of-care therapies for both local and metastatic disease, based on sustained tumoricidal response, anti-tumor immunomodulation, and minimal systemic toxicity. The company operates as a private entity and maintains a corporate website at nanology.us.

Clinical-stage oncology company advancing a local precision approach to solid tumor treatment using the Purcision particle engineering technology platform.

• LSAM-PTX (LSAM-Paclitaxel) for Suspension

  Investigational large surface area microparticle formulation of paclitaxel for intraperitoneal, intratumoral, and intracystic administration in ovarian, prostate, pancreatic, pancreatic mucinous cyst, and lung cancers.

• LSAM-DTX (LSAM-Docetaxel) for Suspension

  Investigational large surface area microparticle formulation of docetaxel for resection bed injection and intravesical instillations in bladder cancer and intratumoral administration in renal cancer.

• LSAM-Cisplatin for Suspension

  Investigational large surface area microparticle formulation of cisplatin for pediatric brain tumors.

• LSAM-PTX for Nebulized Inhalation

  Investigational nebulized inhalation formulation of LSAM-paclitaxel for lung cancer.

• SOR007

  Topical submicron particle paclitaxel suspended in an anhydrous base, under investigation for cutaneous metastases and actinic keratosis.

1. 1Home - NanOlogynanology.us
2. 2About - NanOlogynanology.us
3. 3Products - NanOlogynanology.us
4. 4NanOlogy, LLC (United States) - Wikidatawikidata.org